Add to a list

Inactive Instrument

LOTUS PHARM Share Price OTC Bulletin Board

LTUS

US5457151042

Pharmaceuticals

OTC Markets Traded

End-of-day quote OTC Bulletin Board
- ^USD	-

31/23/31	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
26/21/26	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE

Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	97.36L 84.05L 78.85L 71.82L 1.35Cr 93Cr 1.37Cr 9.24Cr 3.62Cr 47Cr 3.66Cr 3.58Cr 155.13Cr	P/E 2009	3.88x	P/E 2010	4.84x
Enterprise Value	1.44Cr 1.24Cr 1.16Cr 1.06Cr 1.99Cr 137.52Cr 2.02Cr 14Cr 5.35Cr 69Cr 5.4Cr 5.28Cr 229.18Cr	EV / Sales 2009	1.02x	EV / Sales 2010	0.95x
Free-Float	99%	Yield 2009 *	-	Yield 2010	-

31/23/31	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
26/21/26	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE
28/21/28	Lotus Pharmaceuticals : Temasek-backed Vertex expects at least $400 million in new S.E.Asia/India fund	RE
16/12/16	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS from LTUSE	CI
19/12/19	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS.E from LTUS	CI

30/12	Lotus Pharmaceutical Supports Street Medicine Program to Expand Access to Care for Those Most in Need	AQ
06/25/06	Lotus Enters License and Supply Agreement with Adalvo for Semaglutide injection	AQ
12/25/12	Lotus Pharmaceutical Achieves New First-Half Record in Revenue for 2025, While Q2 Impacted by FX and Timing of Lenalidomide Sales	AQ
21/25/21	Lotus announces FDA acceptance of Potential First-to-File ANDA Submission for Voclosporin soft gelatin capsules, a generic equivalent to Lupkynis	AQ
08/24/08	Lotus Achieves Second-Highest Quarterly Performance in Company History with 3Q24 Financial Results	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.37%	-3.44%	+14.85%	+65.22%	4.72TCr
OTSUKA HOLDINGS CO., LTD.	+0.21%	-1.71%	+51.94%	+122.92%	3.96TCr
CIPLA LIMITED	-0.03%	-2.18%	-8.57%	+15.75%	1.21TCr
ZYDUS LIFESCIENCES LIMITED	-1.41%	-6.33%	+13.09%	+72.20%	1.18TCr
KRKA, D. D.	+0.58%	0.00%	+30.65%	+148.80%	911.85Cr
GEDEON RICHTER	-0.46%	-0.77%	+22.42%	+40.20%	756.88Cr
ONO PHARMACEUTICAL CO., LTD.	+1.33%	+1.01%	+44.58%	-11.96%	710.27Cr
GLENMARK PHARMACEUTICALS LIMITED	-1.03%	+1.27%	+16.77%	+200.84%	687.4Cr
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+0.63%	-2.55%	-30.10%	+23.92%	580.8Cr
Average	-0.06%	-0.62%	+17.29%	+75.32%	1.64TCr
Weighted average by Cap.	-0.12%	-2.14%	+23.88%	+82.11%

	2009	2010
Net sales	5.78Cr 4.99Cr 4.68Cr 4.27Cr 8.02Cr 552.88Cr 8.13Cr 55Cr 22Cr 276.99Cr 22Cr 21Cr 921.4Cr	7.27Cr 6.28Cr 5.89Cr 5.36Cr 10Cr 695.08Cr 10Cr 69Cr 27Cr 348.23Cr 27Cr 27Cr 1.16TCr
Net income	1.64Cr 1.42Cr 1.33Cr 1.21Cr 2.28Cr 157.11Cr 2.31Cr 16Cr 6.11Cr 79Cr 6.17Cr 6.04Cr 261.84Cr	1.44Cr 1.25Cr 1.17Cr 1.06Cr 2Cr 137.92Cr 2.03Cr 14Cr 5.37Cr 69Cr 5.42Cr 5.3Cr 229.85Cr
Net Debt	5.29 4.57 4.29 3.91 7.34 506.16 7.44 50.26 19.7 253.59 19.88 19.44 843.54	4.65 4.01 3.76 3.43 6.45 444.29 6.53 44.12 17.29 222.59 17.45 17.07 740.43

LOTUS PHARM Share Price OTC Bulletin Board

Stocks

LTUS

US5457151042

Pharmaceuticals

Valuation: LOTUS PHARM

Latest news : LOTUS PHARM

Press Releases: LOTUS PHARM

Managers and Directors: LOTUS PHARM

Generic Pharmaceuticals

Financials

Company Profile